Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

• Status: Unknown status
• Trial end date: 2020-04-30
• Target enrollment: 0
• Participant gender: All

Summary

To compare clinical outcomes in patients with chronic kidney disease (CKD) presenting with an acute coronary syndrome (ACS) treated with clopidogrel or ticagrelor (both FDA approved and guideline indicated drugs for treating these patients upstream managed medically or with coronary revascularization).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: North Texas Veterans Healthcare System
• Treatments: Clopidogrel; Ticagrelor; Ticlopidine

Criteria

Inclusion Criteria:

• Hospital admission with non-emergent ACS qualifying diagnosis: chest pain, unstable angina or NSTEMI

• A decision to prescribe clopidogrel or ticagrelor in addition to aspirin (DAPT-dual antiplatelet therapy) by the attending physician

• A eGFR< 60 mL/min per 1.73 m.2 (as defined in the EMR or CPRS reported results)

Exclusion Criteria:

• Diagnosis of ST Elevation Myocardial Infarction (STEMI) at admission

• History of intra-cranial hemorrhage

• Bleeding requiring hospitalization, surgery, or transfusion within the past 3 months

• Life expectancy in the opinion of the provider < 6 months

• Chronic antithrombotic therapy

• Known allergy to clopidogrel or ticagrelor

• Patients on hemodialysis